JP2014510704A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510704A5
JP2014510704A5 JP2013546310A JP2013546310A JP2014510704A5 JP 2014510704 A5 JP2014510704 A5 JP 2014510704A5 JP 2013546310 A JP2013546310 A JP 2013546310A JP 2013546310 A JP2013546310 A JP 2013546310A JP 2014510704 A5 JP2014510704 A5 JP 2014510704A5
Authority
JP
Japan
Prior art keywords
pharmaceutical tablet
tablet
pharmaceutical
drug
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013546310A
Other languages
English (en)
Japanese (ja)
Other versions
JP6126014B2 (ja
JP2014510704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/066021 external-priority patent/WO2012088033A2/en
Publication of JP2014510704A publication Critical patent/JP2014510704A/ja
Publication of JP2014510704A5 publication Critical patent/JP2014510704A5/ja
Application granted granted Critical
Publication of JP6126014B2 publication Critical patent/JP6126014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013546310A 2010-12-20 2011-12-20 新規医薬組成物 Active JP6126014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20
US61/424,967 2010-12-20
PCT/US2011/066021 WO2012088033A2 (en) 2010-12-20 2011-12-20 Novel pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017007796A Division JP2017137299A (ja) 2010-12-20 2017-01-19 新規医薬組成物

Publications (3)

Publication Number Publication Date
JP2014510704A JP2014510704A (ja) 2014-05-01
JP2014510704A5 true JP2014510704A5 (enExample) 2015-02-05
JP6126014B2 JP6126014B2 (ja) 2017-05-10

Family

ID=46314827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013546310A Active JP6126014B2 (ja) 2010-12-20 2011-12-20 新規医薬組成物
JP2017007796A Withdrawn JP2017137299A (ja) 2010-12-20 2017-01-19 新規医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017007796A Withdrawn JP2017137299A (ja) 2010-12-20 2017-01-19 新規医薬組成物

Country Status (38)

Country Link
US (5) US20130266649A1 (enExample)
EP (4) EP4159204B1 (enExample)
JP (2) JP6126014B2 (enExample)
KR (1) KR101911109B1 (enExample)
CN (1) CN103998041B (enExample)
AR (2) AR084102A1 (enExample)
AU (1) AU2011349422B2 (enExample)
BR (1) BR112013015602B1 (enExample)
CA (1) CA2822701C (enExample)
CL (1) CL2013001779A1 (enExample)
CR (1) CR20130352A (enExample)
CY (1) CY1123376T1 (enExample)
DK (3) DK4159204T3 (enExample)
DO (1) DOP2013000138A (enExample)
EA (1) EA025198B1 (enExample)
ES (3) ES2982775T3 (enExample)
FI (2) FI4159204T3 (enExample)
HR (3) HRP20240564T1 (enExample)
HU (3) HUE066526T2 (enExample)
IL (1) IL226855A (enExample)
JO (1) JO3594B1 (enExample)
LT (3) LT4159204T (enExample)
MA (1) MA34883B1 (enExample)
MX (1) MX2013007073A (enExample)
MY (1) MY170501A (enExample)
NZ (1) NZ612157A (enExample)
PE (1) PE20140040A1 (enExample)
PH (1) PH12013501209A1 (enExample)
PL (3) PL4159205T3 (enExample)
PT (3) PT4159205T (enExample)
RS (2) RS65496B1 (enExample)
SG (1) SG191054A1 (enExample)
SI (3) SI2654736T1 (enExample)
TW (1) TWI505828B (enExample)
UA (1) UA113158C2 (enExample)
UY (1) UY33818A (enExample)
WO (1) WO2012088033A2 (enExample)
ZA (1) ZA201304189B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
PT2884979T (pt) 2012-08-17 2019-09-04 Hoffmann La Roche Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib
IN2015DN04094A (enExample) * 2012-11-30 2015-10-09 Glaxosmithkline Llc
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
EP4613333A3 (en) 2016-08-10 2025-10-29 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
WO2018095403A1 (zh) 2016-11-25 2018-05-31 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物药物组合物及其制备方法
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
TW202116314A (zh) * 2019-07-11 2021-05-01 美商普雷西斯精密藥品公司 T型鈣離子通道調節劑之調配物及其使用方法
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
PL1761528T3 (pl) * 2004-06-11 2008-05-30 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2009018238A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
CA2668724A1 (en) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
US8414918B2 (en) * 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8822482B2 (en) * 2008-07-08 2014-09-02 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
MX2012003546A (es) 2009-09-23 2012-09-07 Glaxosmithkline Llc Combinacion.
US20120283278A1 (en) 2009-09-23 2012-11-08 Melissa Dumble Combination
MX2012003779A (es) 2009-09-28 2012-06-01 Glaxosmithkline Llc Combinacion.
DK4159217T3 (da) 2009-10-16 2024-08-12 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
AU2010322105B2 (en) 2009-11-17 2014-05-08 Novartis Ag Combination
EP2608790A4 (en) 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Similar Documents

Publication Publication Date Title
JP2014510704A5 (enExample)
HRP20201409T1 (hr) Novi farmaceutski pripravak
CN103599083B (zh) 左旋奥拉西坦缓释片及其制备方法
JP6770946B2 (ja) 2−フルオロ−n−メチル−4−[7−(キノリン−6−イルメチル)イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの錠剤
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
JP6001763B2 (ja) 低用量エンテカビルの経口投与製剤の製造方法
TWI700100B (zh) 用於口服投藥之包含依澤替米貝(ezetimibe)及羅舒伐他汀(rosuvastatin)的複合調配物及其製備方法
CN107530292A (zh) 瑞博西尼片剂
AU2007314282A2 (en) Elvucitabine pharmaceutical compositions
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
CN106176640B (zh) 一种含枸橼酸托法替布的药物组合物及其制备方法
CN104840960A (zh) 抗糖尿病的药物组合物及其制备方法
JP2014516535A5 (enExample)
RU2014140177A (ru) Фармацевтические антиретровирусные композиции
CN105263479A (zh) 调整释放制剂
JP6243351B2 (ja) パーキンソン病の固定投与量薬剤組合せ治療
JP2018150384A (ja) 口腔内崩壊錠及びその製造方法
TWI704918B (zh) 含有細胞周期蛋白抑制劑的藥物製劑及其製備方法
CN102198108B (zh) 一种盐酸西那卡塞片剂或胶囊制备工艺
EP3052130B1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
WO2015085739A1 (zh) 一种多层固体药物剂型
CN107080741A (zh) 吡非尼酮缓释制剂及制备方法
WO2016204657A3 (ru) Способ получения фармацевтической композиции адеметионина и его лекарственной формы
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
CN102675338A (zh) 微粉化普拉格雷及其药用组合物